Summary
Reported 5-FU-induced cardiac side effects may be explained by drug-induced hemodynamic changes and/or by direct myocardial toxicity due to regional drug uptake. This question was studied in 11 animals given constant infusions and 6 animals given bolus 5-FU infusions into the hepatic artery. Six animals, which received normal saline infusion, served as controls. A second aim was to study possible pulmonary drug clearance. Aortic, pulmonary arterial, and coronary sinus plasma 5-FU concentrations were determined during constant and after the bolus infusions of 5-FU. The V5 ECG, aortic, pulmonary arterial, and right atrial pressures were recorded continuously, and cardiac output and coronary sinus blood flow were recorded intermittently in all animals. No significant alterations in hemodynamic variables were seen during constant infusion. After the bolus infusion, an increased arterio-mixed venous oxygen content difference was recorded. Pharmacokinetic data after 3-min infusions indicated pulmonary drug uptake and release; during constant infusions, the data indicated myocardial drug uptake. As there were no alterations in myocardial oxygen demand or supply or in systemic hemodynamics during this myocardial drug uptake, it is likely that the cardiotoxicity is related to the direct effects of the drug on cardiac myocytes.
Similar content being viewed by others
References
Almersjö OE, Gustavsson BG, Regårdh CG, Wåhlen P (1980) Pharmacokinetic studies of 5-fluorouracil after oral and intravenous administration in man. Acta Pharmacol Toxicol 46: 329
Andersson M, Billström Å, Domellöf L, Gustavsson B (1987) Cardio-pulmonary elimination of 5-fluorouracil after bolus injection in the hepatic artery. Eur J Surg Oncol 13: 35
Ansfield FJ, Schroeder JM, Curreri AR (1962) Five years clinical experience with 5-FU. JAMA 181: 295
Carrico CK, Glazer RI (1979) Augmentation by thymidine of the incorporation and distribution of 5-fluorouracil into ribosomal RNA. Biochem Biophys Res Commun 87: 664
Collins JM, Dedrick RL, King FG, Speyer JL, Myers CE (1980) Nonlinear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal routes. Clin Pharmacol Ther 28: 235
Donehower RC, Myers CE, Chabner BA (1979) Minireview. New developments on the mechanisms of action of antineoplastic drugs. Life Sci 24: 1
Ganz W, Tamura K, Marcus HS, Donoso R, Yoshida S, Swan HJ (1971) Measurement of coronary sinus blood flow by continuous thermodilution in man. Circulation 44: 181
Gustavsson BG, Brandberg Å, Regårdh CG, Almersjö OE (1979) Regional and systemic serum concentrations of 5-fluorouracil after portal and intravenous infusion: an experimental study in dogs. J Pharmacokinet Biopharm 7: 665
Levett JM, Replogle RL (1979) Thermodilution cardiac output: a critical analysis and review of the literature. J Surg Res 27: 392
Liss RH, Chadwick M (1974) Correlation of 5-fluorouracil (NSC-19893) distribution in rodents with toxicity and chemotherapy in man. Cancer Chemother Rep 58: 777
Mukherjee KL, Boohar J, Wentland D, Ansfield FJ, Heidelberger C (1963) Studies of fluorinated pyrimidines: XVI. Metabolism of 5-fluorouracil-2-C14 and 5-fluoro-2′-deoxyuridine-2-C14 in cancer patients. Cancer Res 23: 49
Myers CE, Diasio R, Eliot HM, Chabner BA (1976) Pharmacokinetics of the flourinated pyrimidines: implications for their clinical use. Cancer Treat Rev 3: 175
Nath S, Häggmark S, Johansson G, Reiz S (1986) Differential depressant and electrophysiological cardiotoxicity of local anaesthetics — an experimental study with special reference to lidocaine and bupivacaine. Anesth Analg 65: 1263
Pottage A, Holt S, Ludgate S, Langlands AO (1978) Fluorouracil cardiotoxicity. Br Med J 1: 547
Roth A, Kolaric K, Popovic S (1975) Cardiotoxicity of 5-fluorouracil (NSC-19893). Cancer Chemother Rep 59: 1051
Sanani S, Spaulding MB, Masud ARZ, Canty R (1981) 5-FU cardiotoxicity. Cancer Treat Rep 65: 1123
Spremulli EN, Cummings FJ, Crabtee GW, LaBresh K, Jordan M, Calabresi P (1983) Hemodynamic effects of potentially useful antineoplastic agents. JNCI 70: 499
Wagner JG, Gyves JW, Stetson PL, Walker-Andrews SC, Wollner IS, Cochran MK, Ensminger WD (1986) Steady-state nonlinear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients. Cancer Res 46: 1499
Woodcock TM, Martin DS, Damin LEM, Kemendy NE, Young CW (1980) Clinical trials with thymidine and fluorouracil: a phase I and clinical pharmacologic evaluation. Cancer 45: 1135
Author information
Authors and Affiliations
Additional information
This study was supported in part by grants from Lions Foundation, Umeå and financial support from Roche, Stockholm, Sweden
Rights and permissions
About this article
Cite this article
Andersson, M., Domellöf, L., Häggmark, S. et al. Cardiopulmonary hemodynamics and pharmacokinetics after hepatic intraarterial infusion of 5-fluorouracil (5-FU). Cancer Chemother. Pharmacol. 22, 251–255 (1988). https://doi.org/10.1007/BF00273420
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00273420